Available Technology

Albumin Binding Immunomodulatory Compositions

Patent Abstract: 
The invention relates to molecules wherein Evan’s Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous albumin that increases the safety and the potency of molecular vaccines. As such, the molecular entities provided here enable efficient delivery and prolonged retention in lymph nodes and reduce systemic toxicity of Evans Blue and enhanced the therapeutic potency of molecular vaccines.
Patent Number: 
Internal Laboratory Ref #: 
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin